BioHealth News Archive
RegenxBio reaches licensing deal with Clearside Biomedical – Washington Business Journal
RegenxBio Inc. just locked in another deal — this one with a company working to treat eye diseases. The Rockville biotech has reached a…
Read More
FDA Approval of Roche Cancer Drug Confirms Beginning of New Oncology Era | The Motley Fool
With nothing more than a passing glance, the U.S. Food & Drug Administration's (FDA) approval of Roche Holdings' (OTC:RHHBY) cancer drug entrectinib last month…
Read More
First hint that body’s ‘biological age’ can be reversed
A small clinical study in California has suggested for the first time that it might be possible to reverse the body’s epigenetic clock, which…
Read More
Baltimore-based Capsulomics wins first place at Patriot Boot Camp in Utah – Technical.ly Baltimore
Baltimore-based Capsulomics won the top award in Utah last month at a pitch competition that was part of a boot camp for early-stage companies…
Read More
Maryland Startup Developing AI-Enabled Drug Discovery Technology, Insilico Medicine, Just Raised $37M in Funding from Leading Chinese VC Firm · BioBuzz
In the world of drug discovery and development, there is increasing pressure to get novel products to market faster, cheaper and ahead of the…
Read More
What Does It Take to Build A Globally Competitive Biohealth Cluster? · BioBuzz
The BioHealth Capital Region (BHCR) continues to thrive and currently occupies the fourth spot in the most recent Genetic Engineering & Biotechnology (GEN) top…
Read More
United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review
United Therapeutics Corporation (UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for…
Read More
How Top Companies Attract, Engage and Retain Their BioHealth Workforce · BioBuzz
Are you finding it harder to recruit, hire and retain the biotech workforce you need? Well, you’re not alone. With the demand for talent at…
Read More
Viela Bio IPO: At Phase 3 Of Development With Positive Results – VIELA BIO, INC. (Pending:VIE) | Seeking Alpha
With product candidates acquired from AstraZeneca (AZN) and MedImmune, Viela Bio (VIE) is clinical-stage biotechnology to be followed carefully. Besides, at Phase 3 of…
Read More
9 health tech trends drawing venture capital
Venture funding for digital health companies reached an all-time high in the first half of 2019, totaling $5.1 billion across 318 deals, according to…
Read More
QIAGEN Announces Change in Global Sales Structure | Technology Networks
QIAGEN N.V. has announced that it has decided to integrate its global sales resources into its Business Areas (Life Sciences, Molecular Diagnostics and Bioinformatics).…
Read More
New Ways of Working Together to Heal the World at Women Building Bio – Sept. 19.
Spotlights on Inspiring New Collaborative Approaches to Discovery and Development of Treatments and Cures {iframe}https://www.vabio.org/events/EventDetails.aspx?id=1239700&group=&utm_source=email&utm_medium=email&utm_campaign=Virginia%20Bio{/iframe}
Read More
Scientists discover hidden differences among cells that may help them evade drug therapy | EurekAlert! Science News
University of Maryland researchers have discovered that seemingly identical cells can use different protein molecules to carry out the same function in an important…
Read MoreImmunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board – Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D.,…
Read More
Save the Date: BioHealth Capital Region Investment Conference October 15 + 16
By invitation only: For questions email BHI@BioHealthInnovation.org Gaithersburg, MD {iframe}http://www.biohealthinnovation.org/events/icalrepeat.detail/2019/10/15/1058/-/biohealth-capital-region-investment-conference{/iframe}
Read More